tirzepatide cas number 2023788-19-2 Tirzepatide
Description
[1] [2] Age and diabetes type: Ozempic is not recommended for those under 18 years of age and is not indicated for type 1 diabetes or diabetic ketoacidosis
Huang, E
Among them, retatrutide has shown significant clinical advantages in phase II clinical trials, reducing the weight of obese patients by up to 24.2% in 48 weeks and lowering the HbA1c of type 2 diabetes patients by 2.2% in 36 weeks ( 3.3.2 Regulation of hepatic lipid metabolism Triple receptor agonists exhibit promising synergistic effects on hepatic lipid metabolism, a central pathological feature in MASLD
doi: 10.1155/2012/146154
